In a report released today, Josh Jennings from Cowen & Co. reiterated a Buy rating on Cerus Corp (NASDAQ: CERS), with a price target of $9.50. The company’s shares closed yesterday at $7.41, close to its 52-week high of $7.93.
According to TipRanks.com, Jennings is a 3-star analyst with an average return of 3.0% and a 57.6% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, K2M Group Holdings, and Cytosorbents Corp.
Cerus Corp has an analyst consensus of Moderate Buy, with a price target consensus of $9.25, which is a 24.8% upside from current levels. In a report issued on July 19, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $9 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.93 and a one-year low of $2.14. Currently, Cerus Corp has an average volume of 1.01M.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. Last month, Laurence Corash, the CSO of CERS bought 35,000 shares for a total of $146,650.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. It produces blood system for platelets and plasma. It markets its products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
